EpilepsyACTELIN 2NCT07796984
Study of the Intracerebral Electrophysiological Signature in the Epileptic Patient
An observational study of Epilepsy, run by University Hospital, Toulouse at 1 site in France.
Trial summary
As part of the clinical management of certain severe, drug-resistant forms of epilepsy, it is necessary to implant electrodes in the brain to identify the epileptic network prior to potential neurosurgical resection of the source zones. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Epilepsy
- What is being tested?
- Cognitive tasks in the form of questionnaires
- How many people
- 75 participants
- Where
- 1 siteFrance
- Study dates
- 1 Oct 2026to 31 Oct 2031
- How long will I take part?
- 3 Weeks
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients with drug-resistant epilepsy hospitalized for stereo-electroencephalography
Who may be able to join
- Patient with drug-resistant focal epilepsy undergoing SEEG evaluation as part of the pre-surgical workup for epilepsy
- Intellectual capacity sufficient to perform cognitive tasks, receive information about the study procedure, and understand the information sheet
Who cannot join
- Patients already participating in another research project that prohibits participation in another study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Electrophysiologie cérébrale, épilepsie, sommeil, Hôpital Pierre Paul Riquet
Toulouse, Oui, 31000
Emeline Muller, 0561778707 ext. +33, muller.E@chu-toulouse.Fr
About this study
Official title: Study of the Intracerebral Electrophysiological Signature of Cognitive Processes and Functional Mapping in Patients With Drug-resistant Epilepsy
As part of the clinical management of certain severe, drug-resistant forms of epilepsy, it is necessary to implant electrodes in the brain to identify the epileptic network prior to potential neurosurgical resection of the source zones. This standardized procedure, known as Stereo-Electroencephalography (SEEG), was developed in France in the 1960s. The electrodes remain implanted for several days-typically two weeks-while awaiting spontaneous epileptic seizures. During this period, the patient remains hospitalized, and their electroencephalographic activity is recorded around the clock.
Patients can be asked to perform cognitive tasks (such as tasks involving memory, attention, vision, language, and decision-making) while awake or asleep; the results can then be correlated with the intracerebral electroencephalographic activity recorded simultaneously as part of their clinical care. This approach makes it possible to capture the electrophysiological signatures of specific cognitive processes, thereby enabling researchers to: 1) create a brain map of electrophysiological signatures, 2) improve standard models of cognitive function, and 3) study the dysfunction of these processes in epilepsy.
- Conditions
- Epilepsy
- Being tested
- Cognitive tasks in the form of questionnaires
- Keywords
- epilepsy, cognitive task, stereoelectroencephalography
- Medical subject headings
- Epilepsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cognitive tasks in the form of questionnairesOther
During their hospitalization for SEEG, patients will perform cognitive tasks to assess memory, vision, attention, language, and decision-making.
| Study group | Role | What they receive |
|---|---|---|
| Patients hospitalized for SEEG with cognitive tasks | Not described Receives: Other: Cognitive tasks in the form of questionnaires |
What is being measured
The primary outcome is the main question the study is designed to answer.
Construction of a database of electrophysiological signatures of various cognitive functions
Correlation of performance on a task involving a neurocognitive process with characteristics of brain activity recorded during the task (electrophysiological signature) using intracranial stereo-electroencephalography (SEEG) electrodes.
Measured: 3 weeks after the inclusion
Secondary outcomes (2)
Evaluation of the impact of epilepsy on these electrophysiological signatures
Significant impact of the patient's epilepsy on the normal electrophysiological signature expected during certain cognitive processes.
Measured: 3 weeks after the inclusion
Determine whether a given brain region is dysfunctional in certain epileptic patients by comparing it with the atlas of normal physiological signatures.
Identification of a dysfunctional brain region in an epileptic patient if the electrophysiological signature differs significantly from that expected based on the atlas.
Measured: 3 weeks after the inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2026
- Study start1 Oct 2026 (estimated)
- Primary completion1 Oct 2031 (estimated)
- Study completion31 Oct 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EpilepsyStudies of the same condition, open and under way.
- More trials run by University Hospital, ToulouseThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 75 participants (estimated)
- Target duration
- 3 Weeks
Sponsor and investigators
- Lead sponsor
- University Hospital, Toulouse
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07796984
- Sponsor's protocol ID
- RC31/25/0562
- Other IDs
- ID-RCB
- Acronym
- ACTELIN 2
- Status last verified
- Aug 2026
- First submitted
- 27 Aug 2026
- Last updated
- 1 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Intracerebral Electrophysiological Signature of Cognitive Processes and Functional Mapping in Patients With Drug-resistant Epilepsy
- ClinicalTrials.gov ID
- NCT07796984
- Acronym / sponsor ID
- ACTELIN 2 / RC31/25/0562
- Conditions
- Epilepsy
- Keywords
- epilepsy, cognitive task, stereoelectroencephalography
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 75 participants (estimated)
- Lead sponsor
- University Hospital, ToulouseUniversity, hospital or other
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- 1 Oct 2031 (estimated)
- Study completion
- 31 Oct 2031 (estimated)
- First posted
- 1 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
As part of the clinical management of certain severe, drug-resistant forms of epilepsy, it is necessary to implant electrodes in the brain to identify the epileptic network prior to potential neurosurgical resection of the source zones. This standardized procedure, known as Stereo-Electroencephalography (SEEG), was developed in France in the 1960s. The electrodes remain implanted for several days-typically two weeks-while awaiting spontaneous epileptic seizures. During this period, the patient remains hospitalized, and their electroencephalographic activity is recorded around the clock.
Patients can be asked to perform cognitive tasks (such as tasks involving memory, attention, vision, language, and decision-making) while awake or asleep; the results can then be correlated with the intracerebral electroencephalographic activity recorded simultaneously as part of their clinical care. This approach makes it possible to capture the electrophysiological signatures of specific cognitive processes, thereby enabling researchers to: 1) create a brain map of electrophysiological signatures, 2) improve standard models of cognitive function, and 3) study the dysfunction of these processes in epilepsy.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Weeks
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients hospitalized for SEEG with cognitive tasks | – | Other: Cognitive tasks in the form of questionnaires |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients with drug-resistant epilepsy hospitalized for stereo-electroencephalography
Key inclusion criteria (2 listed)
- Patient with drug-resistant focal epilepsy undergoing SEEG evaluation as part of the pre-surgical workup for epilepsy
- Intellectual capacity sufficient to perform cognitive tasks, receive information about the study procedure, and understand the information sheet
Key exclusion criteria (1 listed)
- Patients already participating in another research project that prohibits participation in another study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cognitive tasks in the form of questionnairesDuring their hospitalization for SEEG, patients will perform cognitive tasks to assess memory, vision, attention, language, and decision-making. | Other | Patients hospitalized for SEEG with cognitive tasks |
Primary outcome
Construction of a database of electrophysiological signatures of various cognitive functions
Time frame: 3 weeks after the inclusion
Correlation of performance on a task involving a neurocognitive process with characteristics of brain activity recorded during the task (electrophysiological signature) using intracranial stereo-electroencephalography (SEEG) electrodes.
2 secondary outcomes
Evaluation of the impact of epilepsy on these electrophysiological signatures
Time frame: 3 weeks after the inclusion
Determine whether a given brain region is dysfunctional in certain epileptic patients by comparing it with the atlas of normal physiological signatures.
Time frame: 3 weeks after the inclusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Epilepsy
Not yet recruiting
Clinical Trial of SEEG for Drug-resistant Epilepsy
Drug-Resistant Epilepsy
RecruitingPhase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Seizures, Lennox Gastaut Syndrome
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Focal Seizure, Epilepsy
Active, not recruitingObservational study
Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)
Traumatic Brain Injury, Post-traumatic Epilepsy
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Focal Seizure, Epilepsy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Epilepsy, run by University Hospital, Toulouse at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jonathan Curot, PHD (05 61 77 94 88 ext. +33, curot.j@chu-toulouse.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Construction of a database of electrophysiological signatures of various cognitive functions (time frame: 3 weeks after the inclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2026.